3/13
09:00 am
omer
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder
Low
Report
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder
3/13
02:08 am
omer
Omeros Co. (NASDAQ: OMER) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Omeros Co. (NASDAQ: OMER) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/5
11:06 pm
omer
Omeros Co. (NASDAQ: OMER) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Omeros Co. (NASDAQ: OMER) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/20
05:46 pm
omer
Omeros Co. (NASDAQ: OMER) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Medium
Report
Omeros Co. (NASDAQ: OMER) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
2/20
09:39 am
omer
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA [Yahoo! Finance]
Low
Report
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA [Yahoo! Finance]
2/20
09:10 am
omer
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
Low
Report
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
2/14
09:00 am
omer
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
Low
Report
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
2/10
09:54 am
omer
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program [Yahoo! Finance]
Low
Report
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program [Yahoo! Finance]
2/10
09:00 am
omer
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
Low
Report
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
1/17
09:17 am
omer
Omeros Co. (NASDAQ: OMER) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Omeros Co. (NASDAQ: OMER) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
1/16
12:28 pm
omer
Omeros Co. (NASDAQ: OMER) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Low
Report
Omeros Co. (NASDAQ: OMER) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
1/16
09:46 am
omer
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint [Yahoo! Finance]
Low
Report
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint [Yahoo! Finance]
1/16
09:15 am
omer
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
Medium
Report
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
12/27
06:53 am
omer
When Can We Expect A Profit From Omeros Corporation (NASDAQ:OMER)? [Yahoo! Finance]
High
Report
When Can We Expect A Profit From Omeros Corporation (NASDAQ:OMER)? [Yahoo! Finance]
12/23
07:27 am
omer
Omeros Co. (NASDAQ: OMER) is now covered by analysts at D. Boral Capital. They set a "buy" rating and a $36.00 price target on the stock.
Low
Report
Omeros Co. (NASDAQ: OMER) is now covered by analysts at D. Boral Capital. They set a "buy" rating and a $36.00 price target on the stock.
12/20
08:19 am
omer
Omeros Co. (NASDAQ: OMER) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
High
Report
Omeros Co. (NASDAQ: OMER) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
12/19
11:00 am
omer
Omeros Reports Narsoplimab TA-TMA Trial Success; Stock Surges [Yahoo! Finance]
High
Report
Omeros Reports Narsoplimab TA-TMA Trial Success; Stock Surges [Yahoo! Finance]
12/19
09:15 am
omer
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
High
Report
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA